Association analysis found GLP-1 drugs were linked to improved benign prostatic hyperplasia outcomes, adding urological benefits to their expanding clinical profile.
Key findingAssociation analysis found GLP-1 drugs were linked to improved benign prostatic hyperplasia outcomes
What the researchers found
Association analysis found GLP-1 drugs were linked to improved benign prostatic hyperplasia outcomes, adding urological benefits to their expanding clinical profile.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.
Acta neuropsychiatrica, 37, e50
Citation
Au, Hezekiah C T; Zheng, Yang Jing; Le, Gia Han; Wong, Sabrina; Teopiz, Kayla M; Kwan, Angela T H; Gill, Hartej; Badulescu, Sebastian; Valentino, Kyle; Rosenblat, Joshua D; Mansur, Rodrigo B; McIntyre, Roger S. (2025). Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.. Acta neuropsychiatrica, 37, e50. https://doi.org/10.1017/neu.2025.4